[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"levobupivacaine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:levobupivacaine":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100639984","plasma-kinetics-of-levobupivacaine-after-transversus-abdominis-plane-tap-block-in-abdominal-surgery-100639984",false,"NCT07581275","Plasma Kinetics of Levobupivacaine After Transversus Abdominis Plane (TAP) Block in Abdominal Surgery","Plasma Kinetics of Levobupivacaine After Transversus Abdominis Plane (TAP) Block in Abdominal Surgery: A Prospective Study and Definition of a Safety Window for Intravenous Lidocaine Administration","LEVO-TAP-PK","Inclusion Criteria:\n\n* Age ≥18 years\n* Scheduled elective abdominal surgery under general anesthesia\n* Planned ultrasound-guided TAP block as part of standard perioperative analgesic care\n* Able to understand and speak French sufficiently to understand the study information and consent form\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent\n* Known allergy or hypersensitivity to amide local anesthetics\n* Severe hepatic impairment\n* Renal impairment (estimated glomerular filtration rate \\\u003C50 mL\u002Fmin\u002F1.73 m²)\n* Contraindication to repeated blood sampling or inability to complete the sampling schedule\n* Participation in another clinical study that could affect absorption, distribution, metabolism, or elimination of local anesthetics\n* Pregnancy\n* Emergency surgery or life-threatening urgent condition\n* Immediate postoperative instability requiring intensive care transfer (e.g., hemodynamic instability)\n* Inability to understand French sufficiently for study information and consent\n* Persons requiring special legal protection for consent (e.g., minors, guardianship, incapacity to consent)","ALL","18 Years","75 Years",{"count":21,"type":22},26,"ESTIMATED","OBSERVATIONAL","This prospective single-center observational pharmacokinetic study will evaluate plasma levobupivacaine concentrations after ultrasound-guided transversus abdominis plane (TAP) block in adult patients undergoing elective abdominal surgery under general anesthesia at CHU Liège. Participants receiving TAP block as part of standard clinical care (levobupivacaine 0.375%, total volume 40 mL, maximum dose 150 mg) will undergo serial blood sampling at 3, 7, 15, 30, 60, 120, and 180 minutes after block completion. Plasma levobupivacaine concentrations will be measured using validated LC-MS\u002FMS methods. The primary objectives are to estimate maximum plasma concentration (Cmax) and time to maximum concentration (Tmax). Secondary objectives include characterization of the concentration-time profile, AUC0-180, interindividual variability, and exploratory associations with clinical factors (age, sex, BMI, type of surgery). The study also aims to inform a pragmatic safety window for subsequent intravenous lidocaine infusion used in multimodal analgesia protocols. Approximately 26 participants will be enrolled. No modification of routine anesthesia or analgesic care is required apart from study-related blood sampling.",[26,27,28,29,30],"Abdominal Surgery Patients","Transversus Abdominis Plane (TAP) Block","Pharmacokinetic Analysis","Levobupivacaine","Local Anaesthetic Systemic Toxicity","NOT_YET_RECRUITING","2026-05-06",{"date":34,"type":35},"2026-05-12","ACTUAL",{"date":37,"type":22},"2026-07-01",{"date":39,"type":22},"2026-12-15",{"name":41,"class":42},"University of Liege","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100563054","local-levobupivacaine-for-pain-relief-after-endoscopic-submucosal-dissection-for-esophageal-lesions-100563054","NCT06611176","Local LevoBupivacaine for Pain Relief After Endoscopic Submucosal Dissection for Esophageal Lesions","Local Levobupivacaine for Pain Relief After Endoscopic Submucosal Dissection for Esophageal Lesions: a Randomized Controlled Trial","BESD-RCT","Inclusion Criteria:\n\n* Patients age ≥18 years at time of consent\n* Visible lesion in the esophagus, minimum diameter of the lesion ≥20 mm\n* Scheduled for esophageal ESD\n* Informed consent\n\nExclusion Criteria:\n\n* Presence of multiple lesions requiring two or more separate endoscopic resections\n* History of esophageal surgery other than fundoplications\n* History of esophageal ablation therapy\n* History of radiotherapy of the esophagus\n* Esophageal varices\n* Prior endoscopic resection in the same area\n* Uncontrolled coagulopathy\n* Severe medical comorbidities precluding endoscopy\n* Allergy to LB or other amide-type local anaesthesia\n* Current regular use of opioids\n* Other aetiology causing pain similar to post-ESD pain\n* Inability to assess pain due to severe psychiatric or neurological disease\n* Insufficient command of Dutch language\n* Brugada syndrome\n* Incapacitated patients",{"count":52,"type":22},88,"INTERVENTIONAL",[55],"NA","Endoscopic submucosal dissection (ESD) is commonly performed for (pre)cancerous lesions in the esophagus. Following ESD, post-procedural chest pain is seen in many patients. Studies have shown that local bupivacaine (BP) into the residual submucosal layer of the resection wound after gastric ESD could reduce post-procedural pain rates effectively. Levobupivacaine (LB) is equipotent to BP regarding analgesic effects, but has a better safety profile. No studies have been performed to evaluate the efficacy of LB after esophageal ESD to reduce pain. Therefore, we want to evaluate the effect on post-procedural pain of local application of LB during esophageal ESD.",[58,29],"Endoscopic Submucosal Dissection",[60,61,62,63],"endoscopic submucosal dissection","ESD","esophagus","analgesic","RECRUITING","2024-11-27",{"date":67,"type":35},"2024-12-02",{"date":69,"type":35},"2024-10-24",{"date":71,"type":22},"2026-03-30",{"name":73,"class":42},"Laura Boer",3]